American Society of Hematology

Fig. 3.

$Fig. 3. Vaccine regimens including FL as a vaccine adjuvant were effective in boosting the precursor frequency of IFN-γ–secreting HER-2/neu–specific T cells. / Data are shown as the preimmunization and postimmunization IFN-γ T-cell response, as measured by 10-day ELISPOT, for the 4 patients who completed all 6 vaccines with FL alone as adjuvant (○) and the 4 patients who completed all 6 vaccines with FL and GM-CSF as a vaccine adjuvant (□). (A) T-cell responses specific for HER-2/neu peptide p776. (B) T-cell responses specific for HER-2/neu peptide p927. (C) T-cell responses specific for HER-2/neu peptide p1166. (D) Data of IFN-γ–producing T-cell responses directed against the HER-2/neu ICD protein. Data are expressed as antigen-specific T-cell precursors per 106 unfractionated PBMCs. Each symbol represents data on an individual patient as the mean and standard deviation of triplicate evaluations. Bold bars indicate the mean response for that group.$

Vaccine regimens including FL as a vaccine adjuvant were effective in boosting the precursor frequency of IFN-γ–secreting HER-2/neu–specific T cells.

Data are shown as the preimmunization and postimmunization IFN-γ T-cell response, as measured by 10-day ELISPOT, for the 4 patients who completed all 6 vaccines with FL alone as adjuvant (○) and the 4 patients who completed all 6 vaccines with FL and GM-CSF as a vaccine adjuvant (□). (A) T-cell responses specific for HER-2/neu peptide p776. (B) T-cell responses specific for HER-2/neu peptide p927. (C) T-cell responses specific for HER-2/neu peptide p1166. (D) Data of IFN-γ–producing T-cell responses directed against the HER-2/neu ICD protein. Data are expressed as antigen-specific T-cell precursors per 10⁶ unfractionated PBMCs. Each symbol represents data on an individual patient as the mean and standard deviation of triplicate evaluations. Bold bars indicate the mean response for that group.

This Feature Is Available To Subscribers Only